Pharmaceutical - Nexavar


Current filters:


Popular Filters

1 to 25 of 34 results

Bayer’s Nexavar cleared in Japan for differentiated thyroid cancer

Bayer’s Nexavar cleared in Japan for differentiated thyroid cancer


Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved German pharma major Bayer’s oral…


EMA recommends extending use of Bayer’s Nexavar


The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…


Transgene, Lee’s Pharma and SillaJen confirm clinical development plan for Pexa-Vec


France’s Transgene, Hong Kong-based Lee’s Pharmaceutical and South Korea’s SillaJen have unveiled…

BayerLee's PharmaceuticalNexavarOncologyPexa-VecPharmaceuticalResearchSillaJenTransgene

Nexavar disappoints in Ph III liver cancer study

Nexavar disappoints in Ph III liver cancer study


German pharma major Bayer and Onyx Pharmaceuticals, now a subsidiary of US biotech firm Amgen say that…

AmgenBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan


There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Liver cancer market to nearly treble in size to $1.4 billion by 2019

Liver cancer market to nearly treble in size to $1.4 billion by 2019


The value of the hepatocellular cancer (HCC) market is set to grow by a massive 172% and hit $1.4 billion…

BayerEuropeMarkets & MarketingNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Nexavar gains FDA priority review for thyroid cancer sNDA


German drug major Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX), which has just agreed…

BayerBiotechnologyNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

BioAlliance updates on Livatag development


French orphan cancer drug developer BioAlliance Pharma (Euronext Paris: BIO) says that the International…

BioAlliance PharmaLivatagNexavarOncologyPharmaceuticalResearch

Indian patent appeal board upholds compulsory license on Bayer's Nexavar


After much delay, the verdict into German pharmaceutical major Bayer's (BAYN: DE) appeal against the…

Asia-PacificBayerGenericsNatco PharmaNexavarOncologyPatentsPharmaceutical

AVEO/Astellas' kidney cancer drug tivozanib fails to beat Nexavar


US biotech AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TYO: 4503) have announced…

Astellas PharmaAVEO OncologyBayerBiotechnologyNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchtivozanib

German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta


The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit…


Positive Ph III results for Bayer's Nexavar in thyroid cancer


German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) this morning revealed…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

Nexavar use in Chinese patients nearly doubled in 2012


Use of Nexavar (sorafenib, from Bayer [BAYN: DE] and Onyx Pharmaceuticals) has nearly doubled in first-line…

AlimtaAsia-PacificBayerBiotechnologyEli LillyMarkets & MarketingNexavarOncologyPharmaceutical

India's IPAB rejects Bayer's "stay petition" regarding Nexavar


Over the weekend, the Intellectual Property Appellate Board (IPAB) of Chennai, India, has dismissed the…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Bayer attempts to block generic Nexavar in India again slammed by MSF


German drug major Bayer (BAYN: DE) yesterday headed to India's Intellectual Property Appellate Board…


Indian hearings on Bayer Nexavar compulsory license delayed


India's Intellectual Property Appellate Board (IPAB) in Chennai has postponed hearing the appeal by German…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Adding Tarceva to Nexavar no better than Nexavar alone for liver cancer


A Phase III trial evaluating the efficacy and safety of the addition of Roche's Tarceva (erlotinib) tablets…

Astellas PharmaBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchTarceva

Bristol-Myers brivanib fails in Ph III liver cancer trial


US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday reported results of the Phase III BRISK-FL clinical…

Bristol-Myers SquibbbrivanibNexavarOncologyPharmaceuticalResearch

1 to 25 of 34 results

Back to top